LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer

Source: CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*
Download Slideset
January 19-21, 2023; San Fransico, California
Pembrolizumab plus lenvatinib and chemotherapy showed a manageable safety profile and preliminary antitumor activity in patients with advanced gastroesophageal cancers.
Format: Microsoft PowerPoint (.ppt)
File Size: 131 KB
Released: January 25, 2023

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme Corp.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings